Pages that link to "Q38163255"
Jump to navigation
Jump to search
The following pages link to Antibody-drug conjugates: current status and future directions (Q38163255):
Displaying 50 items.
- Linkers Having a Crucial Role in Antibody-Drug Conjugates (Q26752763) (← links)
- Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs) (Q26768654) (← links)
- Antibody-drug conjugates--an emerging class of cancer treatment (Q26770312) (← links)
- Antibody-drug conjugates as novel anti-cancer chemotherapeutics (Q26800175) (← links)
- Antibody Drug Conjugates: Preclinical Considerations (Q27022321) (← links)
- Recent advances in T-cell engineering for use in immunotherapy (Q28080312) (← links)
- Therapeutic aptamers: developmental potential as anticancer drugs (Q28085157) (← links)
- Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry (Q28544658) (← links)
- Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency (Q28546010) (← links)
- Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity. (Q33641923) (← links)
- Novel systemic therapy against malignant pleural mesothelioma (Q33890499) (← links)
- Computational Construction of Antibody-Drug Conjugates Using Surface Lysines as the Antibody Conjugation Site and a Non-cleavable Linker (Q34663010) (← links)
- Miniaturized blood sampling techniques to benefit reduction in mice and refinement in nonhuman primates: applications to bioanalysis in toxicity studies with antibody-drug conjugates (Q35244637) (← links)
- Methods to Make Homogenous Antibody Drug Conjugates (Q35523479) (← links)
- Giant cell tumour of bone: new treatments in development (Q35662668) (← links)
- A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies (Q35764587) (← links)
- Antibody Drug Conjugates: Nonclinical Safety Considerations (Q35967917) (← links)
- Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials (Q36366709) (← links)
- Near-IR Light-Mediated Cleavage of Antibody-Drug Conjugates Using Cyanine Photocages (Q36551221) (← links)
- A "methyl extension" strategy for polyketide natural product linker site validation and its application to dictyostatin (Q36738065) (← links)
- Super enhanced permeability and retention (SUPR) effects in tumors following near infrared photoimmunotherapy (Q36777569) (← links)
- Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists. (Q37066113) (← links)
- Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen (Q37222147) (← links)
- Marine Antibody-Drug Conjugates: Design Strategies and Research Progress. (Q37628646) (← links)
- An Fc domain protein-small molecule conjugate as an enhanced immunomodulator (Q38275191) (← links)
- Drug delivery and release systems for targeted tumor therapy (Q38363691) (← links)
- Current ADC Linker Chemistry (Q38373185) (← links)
- Emerging formats for next-generation antibody drug conjugates (Q38386705) (← links)
- Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection (Q38453769) (← links)
- Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability (Q38489049) (← links)
- Antibodies as a source of anti-infective peptides: an update (Q38539513) (← links)
- Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. (Q38648690) (← links)
- Functionalized protein nanocages as a platform of targeted therapy and immunodetection (Q38664186) (← links)
- Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates. (Q38665164) (← links)
- SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression (Q38704805) (← links)
- Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry. (Q38736346) (← links)
- Synthesis and Evaluation of Paclitaxel-Loaded Gold Nanoparticles for Tumor-Targeted Drug Delivery (Q38740409) (← links)
- ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer. (Q38762359) (← links)
- Genotoxicity assessment of peptide/protein-related biotherapeutics: points to consider before testing (Q38783897) (← links)
- Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives. (Q38854876) (← links)
- Antibody drug conjugates (Q38873862) (← links)
- Controlling toxicity of Peptide-drug conjugates by different chemical linker structures (Q38882129) (← links)
- TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets (Q38920996) (← links)
- Antibody-drug conjugates: recent advances in conjugation and linker chemistries. (Q38981429) (← links)
- Molecular Networking As a Drug Discovery, Drug Metabolism, and Precision Medicine Strategy (Q39008493) (← links)
- Strategies and challenges for the next generation of antibody-drug conjugates (Q39182945) (← links)
- Advances in antibody-drug conjugates: A new era of targeted cancer therapy. (Q39382257) (← links)
- Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice (Q39830501) (← links)
- Current progress in innovative engineered antibodies (Q40077818) (← links)
- Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand (Q40602973) (← links)